This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain. Gabapentin has antihyperalgesic and antiallodynic properties but does not have significant actions as an anti-nociceptive agent. Its mechanisms of action appear to be a complex synergy between increased GABA synthesis, non-NMDA receptor antagonism and binding to the α2δ subunit of voltage dependent calcium channels. The latter action inhibits the release of excitatory neurotransmitters. Clinically, several large randomized controlled trials have demonstrated its effectiveness in the treatment of a variety of neuropathic pain syndromes. Patients with neuropathic pain can expect a mean reduction in pain score of 2.05 points on an 11 point numerical rating scale compared with a reduction of 0.94 points if they had taken the placebo. Around 30% of patients can expect to achieve more than 50% pain relief and a similar number will also experience minor adverse events; the most common of which are somnolence and dizziness. In patients with neuropathic pain due to cancer, higher response rates might be observed with gabapentin when administered with opioids because of a synergistic interaction.
Blom S.Trigeminal neuralgia: its treatment with a new anticonvulsant drug. Lancet1962; i: 839–840.
2.
Swerdlow M.Anticonvulsants in the therapy of neuralgic pain. Pain Clin1986; 1: 9–19.
3.
Lambet A, Laduron P, Mourre C, Jacomet Y, Lazdunski M. Axonal transport of the voltage dependent Na+ channel protein identified by its tetrodotoxin binding site in rat sciatic nerves. Brain Res1985; 345: 153–158.
4.
Devor M, Govrin-Lippman R, Angelides K. Na+ channel immunolocalisation in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neuroscience1993; 13: 1976–1992.
5.
Moll C, Mourre C, Lazdunski M, Ulrich J. Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res1991; 556: 311–316.
6.
Catteral WA.Common modes of drug action on sodium channels: local anaesthetics, antiarrhythmics and antic-onvulsants. Trends Pharmacol Sci1987; 8: 57–65.
7.
McQuay HJ.Pharmacological treatment of neuralgic and neuropathic pain. Cancer Surv1988; 7: 141–159.
8.
Yaari Y, Devor M. Phenytoin suppresses spontaneous ectopic discharge in rat sciatic nerve neuromas. Neurosci Lett1985; 58: 117–122.
9.
Budd K.Sodium valproate in the treatment of pain. In Chadwick D ed. Fourth international symposium on sodium vaplroate and epilepsy. London: Royal Society of Medicine, 1989: 213–216.
10.
Raftery H.The management of post herpetic neuralgia using sodium valproate and amitriptyline. J Irish Med Assoc1979; 72: 399–401.
11.
Peiris JB, Perera GL, Devendra SV, Lionel ND. Sodium valproate in trigeminal neuralgia. Med J Aust1980; 2: 278–278.
12.
Reddy S, Patt R. The benzodiazepines as adjuvant analgesics. J Pain Symptom Manage1994; 9: 510–514.
13.
Fromm GH. Baclofen as an adjuvant analgesic. J Pain Symptom Manage1994; 9: 500–509.
14.
Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double blind study and long term follow-up. Ann Neurol1984; 15: 240–244.
15.
McQuay H, Carroll D, Jadad A, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ1995; 311: 1047–1052.
16.
Wiffen P, Collins S, McQuay H, Corroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database System Rev2000; 2: CD001133.
17.
Elwes RD, Binnie CD. Clinical pharmacokinetics of the newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet1996; 30: 403–415.
18.
Vollmer KO, Anhut H, Thomann P, Wagner F, Jahncken D. Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. Adv Epileptol1989; 17: 209–211.
19.
Turck D, Vollmer KO, Bockbrader H, Sedman A. Dose linearity of the new anticonvulsant gabapentin after multiple oral doses. Eur J Clin Pharmacol1989; 36 (suppl): A310–A310.
20.
Boyd RA, Turck D, Abel RB, Sedman AJ, Bockbrader HN. Effects of age and gender on single dose pharmacokinetics of gabapentin. Epilepsia1999; 40: 474–479.
21.
Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P.Bockbrader H.Pharmacokinetics of gapapentin in subjects with various degrees of renal impairment. Clin Pharmacol Ther1994; 56: 154–159.
Taylor CP. Gabapentin: mechansims of action. In Levy RH, Mattson RH, Meldrum BS eds. Antiepileptic drugs. New York, Raven Press, 1995: 829–841.
24.
Suzdak PD, Jansen JA. A review of preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia1995; 36: 612–626.
25.
Fichter N, Taylor CP, Feuerstein TJ. Nipecotate-induced GABA release from slices of rat caudate-putamen: effects of gapapentin N–S. Arch Pharmacol1996; 345: 35–35.
26.
Kocsis JD, Honmou O. Gabapentin increases GABA-induced depolarisation in rat neonatal optic nerve. Neurosci Lett1994; 169: 181–184.
27.
Kaneko M, Mestre C, Sanchez EH, Hammond DL. Intrathecally administered gabapentin inhibits formalin-evoked nociception and the expression of Fos-like immunoreactivity in the spinal cord of the rat. J Pharmacol Exp Ther2000; 292: 743–751.
28.
Chen S-R, Eisenach JC, McCaslin PP, Pan H-L. Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats. Anesthesiology2000; 92: 500–506.
29.
Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug gabapentin binds to the α2δ subunit of a calcium channel. J Biol Chem1996; 271: 5768–5776.
30.
Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (Neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol1997; 121: 1513–1522.
31.
Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain2000; 85: 405–414.
32.
Dixit R, Bhargava VK, Kaur N. Antinociceptive effect of gabapentin and clinical pharmacology. Methods Find Exp Clin Pharmacol1999; 21: 481–482.
33.
Yoon MH, Yaksh TL. Evaluation of interaction between gabapentin and ibuprofen on the formalin test in rats. Anesthesiology1999; 91: 1006–1013.
34.
Abdi S, Lee DH, Chung JM. The antiallodynic effects of amitriptyline, gabapentin and lidocaine in a rat model of neuropathic pain. Anesth Analg1998; 87:1360–1366.
35.
Pan HL, Eisenach JC, Chen SR. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther1999; 288: 1026–1030.
36.
Rock DM, Kelly KM, Macdonald RL. Gabapentin actions on ligand and voltage-gated responses in cultured rodent neurons. Epilepsy Res1993; 16: 89–98.
37.
Wamil AW, McLean MJ. Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res1994; 17: 1–11.
38.
Welty DF, Shielke GP, Vartanian MG, Taylor CP. Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate. Epilepsy Res1993; 16: 175–181.
39.
Field MJ.McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain1999; 80: 391–398.
40.
Rocha L, Ondarza-Rovira R, Maidment NT. Gabapentin modifies extracellular opioid content in amygdala: a microdialysis study. Epilepsy Res1999; 35: 13–20.
41.
Shimoyama M, Shimoyama N, Inturissi CE, Elliott KJ. Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail flick test. Pain1997; 72: 375–382.
42.
Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain1996; 13: 251–255.
43.
Mellick GA, Mellick LB. Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil1997; 78: 98–105.
44.
Hays H, Woodroffe MA. Using gabapentin to treat neuropathic pain. Can Fam Physician1999; 45: 2109–2112.
45.
Holtrom N. Gabapentin for treatment of thalamic pain syndrome. Palliat Med2000; 14: 167–167.
46.
Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. JAMA1998; 280: 1837–1842.
47.
Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain2001; 94: 215–224.
48.
Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA1998; 280: 1831–1836.
49.
Serpell M, Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain2002; 99: 557–566.
50.
Caraceni A, Zecca E, Martini C, de Conno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage1999; 17: 441–445.
51.
Chandler A, Williams JE. Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital. J Pain Symptom Manage2000; 20: 82–83.
52.
Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin versus amitriptyline in painful diabetic neuropathy: an open label pilot study. J Pain Symptom Manage2000; 20: 280–285.
53.
Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomised double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med1999; 159: 1931–1937.
54.
Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg2000; 91: 185–191.
55.
Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain1999; 83: 389–400.
56.
McQuay H, Tramer M, Nye BA, Carroll D, Wiffen P, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain1996; 68: 217–227.
57.
Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ1995; 310: 452–454.
